Robust non-linear mixed modelling of longitudinal PSA levels after prostate cancer treatment

Statistics in Medicine

Volumn 29, Issue 5, 2010, Pages 573-587

  Subtil, F ^a,b,c,d   Rabilloud, M ^a,b,c,d  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^d HOSPICES CIVILS DE LYON   (France)

Author keywords

Diagnostic test; Longitudinal study; Prostate specific antigen; Robust modelling; Semi parametric Bayesian methods

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; DIAGNOSTIC ACCURACY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MAJOR CLINICAL STUDY; MALE; NONLINEAR SYSTEM; NORMAL DISTRIBUTION; PROGNOSIS; PROSTATE CANCER; SIMULATION; STUDENT T TEST; THERAPY EFFECT;

BAYES THEOREM; BIAS (EPIDEMIOLOGY); COMPUTER SIMULATION; HUMANS; LONGITUDINAL STUDIES; MALE; NEOPLASM RECURRENCE, LOCAL; NONLINEAR DYNAMICS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 76749147802     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3816     Document Type: Article

References (38)

1. Scher HI, Warren M, Heller G. The association between measures of progression and survival in castrate-metastatic prostate cancer. Clinical Cancer Research 2007; 13(5):1488-1492. DOI: 10.1158/1078-0432.CCR-06- 1885.
2. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen M-H. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. The Journal of Urology 2004; 172(5):S42-S47. DOI: 10.1097/01.ju. 0000141845.99899.12.
3. Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. International Journal of Radiation Oncology Biology Physics 2006; 65(4):965-974. DOI: 10.1016/j.ijrobp.2006.04.029.
4. Uchida T, Illing RO, Cathcart PJ, Emberton M. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU National 2006; 98(3):537-539.
5. Blana A, Brown SC, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Pasticier G, Rebillard X, Rewcastle JC, Robertson CN, Thuroff S, Ward JF. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU International 2009. (Advance Access April 17, 2009.); DOI: 10.1111/j.1464-410X.2009.08518.x.
6. Poissonnier L, Chapelon JY, Rouviere O, Curiel L, Bouvier R, Martin X, Dubernard JM, Gelet A. Control of prostate cancer by transrectal HIFU in 227 patients. European Urology 2007; 51(2):381-387. DOI: 10.1016/j.eururo.2006.04.012.
7. Eastham JA, Riedel E, Scardino PT, Shike M, Fleisher M, Schatzkin A, Lanza E, Latkany L, Begg CB. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. The Journal of the American Medical Association 2003; 289(20):2695-2700.
8. Soletormos G, Semjonow A, Sibley PEC, Lamerz R, Petersen PH, Albrecht W, Bialk P, Gion M, Junker F, Schmid H-P, Van Poppel H, On behalf of the European group on Tumor M. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clinical Chemistry 2005; 51(8):1342-1351. DOI: 10.1373/clinchem.2004.046086.
9. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis (2nd edn). Chapman & Hall, CRC: London, 2004.
10. Zagars GK, Pollack A. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer 1993; 72(3):832-842. DOI: 10.1002/1097-0142(19930801)72:3<832::AID-CNCR2820720332>3.0.CO;2-6.
11. Yu M, Law NJ, Taylor JMG, Sandler HM. Joint longitudinal-survival-cure models and their application to prostate cancer. Statistica Sinica 2004; 14:835-862.
12. Vollmer RT, Montana GS. The dynamics of prostate-specific antigen after definitive radiation therapy for prostate cancer. Clinical Cancer Research 1999; 5(12):4119-4125.
13. Taylor JMG, Yu M, Sandler HM. Individualized predictions of disease progression following radiation therapy for prostate cancer. Journal of Clinical Oncology 2005; 23(4):816-825.
14. You B, Perrin P, Freyer G, Ruffion A, Tranchand B, Hénin E, Paparel P, Ribba B, Devonec M, Falandry C, Fournel C, Tod M, Girard P. Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy. Clinical Biochemistry 2008; 41:785-795. DOI: 10.1016/j. clinbiochem.2008.04.001.
15. Bellera CA, Hanley JA, Joseph L, Albertsen PC. Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancer. Annals of Epidemiology 2008; 18(4):270-282.
16. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38(4):963-974.
17. Carroll RJ, Ruppert D. Transformation and Weighting in Regression. Chapman & Hall: London, 1988.
18. Lipsitz SR, Ibrahim J, Molenberghs G. Using a Box-Cox transformation in the analysis of longitudinal data with incomplete responses. Journal of the Royal Statistical Society. Series C, Applied Statistics 2000; 49(3):287-296. DOI: 10.1111/1467-9876.00192.
19. Lange KL, Little RJA, Taylor JMG. Robust statistical modeling using the t distribution. Journal of the American Statistical Association 1989; 84:881-896.
20. Rosa GJM, Padovani CR, Gianola D. Robust linear mixed models with normal/independent distributions and Bayesian MCMC implementation. Biometrical Journal 2003; 45(5):573-590. DOI: 10.1002/bimj. 200390034.
21. Kleinman KP, Ibrahim JG. A semiparametric Bayesian approach to the random effects model. Biometrics 1998; 54(3):921-938.
22. Escobar MD. Estimating normal means with a Dirichlet process prior. Journal of the American Statistical Association 1994; 89(425):268-277.
23. Escobar MD, West M. Computing nonparametric hierarchical models. In Practical Nonparametric and Semiparametric Bayesian Statistics, Dey D, Müller P, Sinha D (eds). Springer: New York, 1998; 1-16.
24. R Development Core Team. R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, 2008.
25. Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford University Press: New York, 2003.
26. Proust-Lima C, Taylor JMG. Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach. Biostatistics 2009; 10(3):535-549. DOI: 10.1093/biostatistics/kxp009.
27. Müller P, Quintana FA. Nonparametric Bayesian data analysis. Statistical Science 2004; 19(1):95-110. DOI: 10.1214/ 088342304000000017.
28. Lavine M. Some aspects of polya tree distributions for statistical modelling. The Annals of Statistics 1992; 20:1222-1235. DOI: 10.1214/aos/1176348767.
29. Pinheiro JC, Liu C, Wu YN. Efficient algorithms for robust estimation in linear mixed-effects models using the multivariate t distribution. Journal of Computational and Graphical Statistics 2001; 10(2):249-276.
30. Reiser B. Measuring the effectiveness of diagnostic markers in the presence of measurement error through the use of ROC curves. Statistics in Medicine 2000; 19(16):2115-2129. DOI: 10.1002/1097-0258(20000830)19: 16<2115::AID-SIM529>3.0.CO;2-M.
31. Zietman AL, DeSilvio ML, Slater JD, Rossi Jr CJ, Miller DW, Adams JA, Shipley WU. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. Journal of the American Medical Association 2005; 294(10):1233-1239. DOI: 10.1001/jama.294.10.1233.
32. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, Bonfrer JM, Incrocci L, Lebesque JV. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology 2006; 24(13):1990-1996. DOI: 10.1200/JCO.2005.05.2530.
33. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, PCCTW Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. Journal of Clinical Oncology 2008; 26(7):1148-1159. DOI: 10.1200/JCO.2007.12.4487.
34. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing 2000; 10:325-337. DOI: 10.1023/A:1008929526011.
35. Geweke J. Bayesian treatment of the independent student-t linear model. Journal of Applied Econometrics 1993; 8(S1):19-40.
36. Escobar MD, West M. Bayesian density estimation and inference using mixtures. Journal of the American Statistical Association 1995; 90(430):577-588.
37. Neal RM. Markov chain sampling methods for Dirichlet process mixture models. Journal of Computational and Graphical Statistics 2000; 9:249-265.
38. Bickel DR. Robust estimators of the mode and skewness of continuous data. Computational Statistics and Data Analysis 2002; 39(2):153-163. DOI: 10.1016/S0167-9473(01)00057-3.